Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction

Inclusion Criteria: * Aged 18 years or older, regardless of gender * In accordance with the 2023 ESC Guidelines for the Management of Acute Coronary Syndromes , meeting the diagnostic criteria for acute myocardial infarction, including typical chest pain lasting for ≥20 minutes, electrocardiographic manifestations of ST-segment elevation (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), and serum high-sensitivity troponin (hs-cTn) levels exceeding the 99th percentile of the upper reference limit at least once with dynamic changes * Presenting for treatment within \<24 hours of symptom onset and scheduled to undergo PCI * The patient or their guardian has signed the informed consent form Exclusion Criteria: * Having contraindications to PCI treatment * Being allergic to Shexiang Baoxin Pills, unable to tolerate them, or having other conditions that prevent completion of the trial drug administration * Being pregnant, planning to become pregnant, or breastfeeding women * Having participated in other clinical studies within 3 months * Being deemed unsuitable for inclusion in this study by the researcher